[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Of Perugia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":209},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,73,107,130,160,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100643241","hfpef-phenotyping-with-echo-clinical-and-biomarkers-100643241",false,"NCT07642921","HFpEF Phenotyping With Echo, Clinical, and Biomarkers","Phenotyping Heart Failure With Preserved Ejection Fraction (HFpEF) Using Echocardiographic, Clinical, and Biomarker Parameters","The EPIC-HFpEF","Inclusion Criteria:\n\n* Patients ≥ 18 years old\n* Signed patient informed consent form (ICF)\n* Diagnosis of chronic (documented HF hospitalization in the last year) or acute decompensated HF shown by signs and symptoms of HF and LVEF \\>50% and, according to guidelines and the universal definition of HF, elevated levels of natriuretic peptides (NT-proBNP ≥300 pg\u002Fml in sinus rhythm or NTproBNP ≥600 pg\u002Fml in atrial fibrillation), at the time of enrolment (10)\n* Echocardiographic evidence of increased estimated LV filling pressures according to current guidelines\n\nExclusion Criteria:\n\n* Planned participation or participation in a clinical trial;\n* Life expectancy \\\u003C 1 year because of non-cardiac causes;\n* History of recent (6 months) infective, or inflammatory, autoimmune or neoplastic diseases.\n* Stage \\>4 CKD (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 15 ml\u002Fmin\u002F1.73m2),\n* Myocardial infarction (increase in cardiac enzymes in combination with symptoms of ischemia or newly developed ischemic ECG changes), coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA in past 3 months;\n* Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalization for exacerbation within 12 months;\n* Congenital heart disease.\n* Primary pulmonary hypertension\n* Moderate-to-severe degenerative (primary) valve disease\n* Cardiomyopathy based on muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), or known pericardial constriction;\n* Implantation of cardioverter defibrillator (ICD) within 3 months\n* Implanted cardiac resynchronization therapy (CRT) and\u002For stable RV pacing.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","2 Years","OBSERVATIONAL","The EPIC-HFpEF registry is a nationwide Italian study that follows people with a specific type of heart failure called HFpEF. About 500 patients will be enrolled from several specialized hospitals and monitored for up to two years, without changing their usual treatment.\n\nThe goal is to better understand this complex condition by identifying different patient \"types\" based on clinical features, heart imaging, and blood markers. Researchers will also look at how these groups are treated in real life and how their disease progresses over time.\n\nBy doing this, the study aims to improve how doctors classify and manage HFpEF, moving toward more personalized and effective care for patients in the future.",[26],"Heart Failure With Preserved Ejection Fraction (HFPEF)",[28,29,30,31,32,33,34],"Phenotyping","Heart Failure","Ejection Fraction","Obesity","Diabetes","Chronic Kidney Disease","HFpEF","NOT_YET_RECRUITING","2026-06-08",{"date":38,"type":39},"2026-06-11","ACTUAL",{"date":41,"type":21},"2026-06-02",{"date":43,"type":21},"2029-07-31",{"name":45,"class":46},"University Of Perugia","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100615132","effects-of-genomic-profiles-on-thromboembolic-risk-in-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-100615132","NCT07288632","Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer","Inclusion Criteria:\n\n* • Patients aged 18 years or older,\n\n  * Cytological or histological confirmation of NSCLC,\n  * Locally advanced or metastatic disease (Stage III-IV),\n  * Patients starting a new anticancer treatment for locally advanced\u002Fmetastatic disease (first or further line of treatment),\n  * Testing for oncogenic (EGFR, KRAS, ALK, ROS1 and PD-1\u002FPD-L1) profile performed,\n  * Written informed consent\n\nExclusion Criteria:\n\n* • Patients received surgery or radiotherapy for lung cancer within the past 3 months before recruitment or chemotherapy within the past 1 months before recruitment,\n\n  * Patients with a history of VTE after cancer diagnosis or evidence of VTE events at enrollment\n  * Continuative use of anticoagulant drugs for any indication (atrial fibrillation or previous VTE)\n  * ECOG performance profile 3 or 4\n  * Life expectancy of less than 3 months",{"count":20,"type":21},"Multicenter, prospective observational study (15 Oncologic Centers, in Italy). The purpose of the study is to assess the thromboembolic potential in patients with oncogene-addicted and wild-type NSCLC. The primary aim of this project is to evaluate the association between oncogene mutations and levels of plasma parameters of the activated coagulation cascade as the plasma levels of TF, thrombin generation, IL 6, vWF, ADAMTS-13 activity, PAI-1, and soluble P-selectin in NSCLC patients. A total of 500 NSCLC patients with a diagnosis (cytologically or histologically confirmed) of locally advanced or metastatic disease will be enrolled in the study, with a ratio of 1:1 for oncogene addicted or wild-type group. The oncogene-addicted group (Group A): patients with at least one oncogene mutation (i.e., patients expressing EGFR mutations, KRAS mutation, ALK or ROS1 rearrangements); the wild type group (Group B): patients without oncogene mutations, categorized in 2 subgroups according to expression of PD1\u002FPD-L1 mutation or not. Patients will be followed up prospectively for 6 months or until death, VTE event, loss to follow-up, or voluntary consent withdrawal.\n\nThis study will evaluate the effects of EGFR, KRAS mutations and ALK\u002FROS 1 and PD-1\u002FPD-L1 rearrangements on the expression of TF and thrombin generation or the interaction between inflammation and endothelial or platelet and cancer cells, in patients with NSCLC. The study will also evaluate the potential correlation between VTE events and the expression of oncogene mutations in patients with NSCLC.\n\nThe results of this study could generate the hypothesis of including the genetic profile as variable for a risk-stratification tools and decision-making algorithms in NSCLC patients.",[56,57],"Venous Thromboembolism (VTE)","NSCLC (Advanced Non-small Cell Lung Cancer)",[59,60,61,62],"NSCLC","venous thromboembolism","genomic profile","activation of coagulation cascade","RECRUITING","2025-12-03",{"date":66,"type":39},"2025-12-17",{"date":68,"type":39},"2024-02-09",{"date":70,"type":21},"2026-02-28",{"name":45,"class":46},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":72},"100581075","safely-delivered-targeted-high-dose-irradiation-followed-by-adoptive-immunotherapy-with-regulatory-and-conventional-t-cells-to-increase-potency-of-hematopoietic-stem-cell-transplantation-in-high-risk-acute-leukemia-100581075","NCT06845592","Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia","SHARP - Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia","SHARP","Inclusion Criteria:\n\n* AML patients\n\n  * Diagnosis of AML with indication to allogeneic hematopoietic cell transplantation.\n  * Diagnosis of adverse genetic risk leukemia or presence of MRD or active disease (bone marrow infiltration 5-30%) at the time of the transplant procedure.\n  * Availability of a hematopoietic stem cell donor (family or unrelated HLA-matched or HLA-haploidentical with the patient) suitable to be treated with G-CSF (10 mcg\u002Fkg\u002Fdie) for a maximum of 7 days and able to tolerate 2 or more leukaphereses.\n  * Age ≥ 18 and ≤ 65 years\n  * ECOG ≤ 2\n  * HCT-CI ≤ 4 (51,52)\n  * Absence of relevant psychiatric diseases\n  * Signature of the informed consent\n\nALL patients\n\n* Diagnosis of ALL, either T or B (Philadelphia negative) or mixed phenotype with indication to allogeneic transplant\n* Presence of MRD or active disease (bone marrow infiltration 5-30%) or patient with ≥ 2nd complete hematologic remission at the time of the transplant procedure.\n* Availability of a hematopoietic stem cell family donor (family or unrelated HLA-matched or HLA-haploidentical with the patient) suitable to be treated with G-CSF (10 mcg\u002Fkg\u002Fdie) for a maximum of 7 days and able to tolerate 2 or more leukaphereses.\n* Age ≥ 18 and ≤ 65 years\n* ECOG ≤ 2\n* HCT-CI ≤ 4\n* Absence of relevant psychiatric diseases\n* Signature of the informed consent\n\nExclusion Criteria:\n\n* AML patients\n\n  * AML in CR MRD-\n  * AML with \\> 5% peripheral blasts or bone marrow infiltration ≥ 30%\n  * Age \\\u003C 18 years or \\> 65 years\n  * ECOG \\> 2\n  * Unacceptable lung, liver, kidney, and\u002For heart function and presence of relevant psychiatric diseases according to clinical judgment\n  * Pregnancy\n  * No signature of the informed consent\n* ALL patients\n\n  * ALL with \\> 5% peripheral blasts or bone marrow infiltration ≥30%\n  * Philadelphia positive ALL\n  * Age \\\u003C 18 years or \\> 65 years\n  * ECOG \\> 2\n  * Unacceptable lung, liver, kidney, and\u002For heart function and presence of relevant psychiatric diseases according to clinical judgment\n  * Pregnancy\n  * No signature of the informed consent","65 Years",{"count":83,"type":21},51,"INTERVENTIONAL",[86],"NA","The study is a monocentric, interventional study that evaluates the efficacy of allogeneic HLA-matched or haploidentical transplantation consisting of an irradiation-based conditioning regimen coupled with donor Treg\u002FTcon adoptive immunotherapy for high-risk acute leukemia patients.",[89,90,91,92],"Acute Myeloid Leukaemia (AML)","Acute Lymphoblastic Leukemia ALL","High Risk Leukaemia","Leukaemia Relapse",[94,17,79,95,96,97,98],"AML","Total marrow\u002Flymphoid irradiation","Treg","Tcon","Relapse","2025-03-01",{"date":101,"type":39},"2025-03-04",{"date":103,"type":39},"2025-02-25",{"date":105,"type":21},"2031-01",{"name":45,"class":46},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100570860","ultrasound-evaluation-of-laryngeal-mask-airway-lma-placement-in-pediatric-patients-and-its-relationship-to-postoperative-complications-100570860","NCT06712732","Ultrasound Evaluation of Laryngeal Mask Airway (LMA) Placement in Pediatric Patients and Its Relationship to Postoperative Complications","Valutazione Ultrasonografica Del Corretto Posizionamento Della Maschera Laringea Nel Paziente Pediatrico","LMAUSPED","Inclusion Criteria:\n\n* Patients undergoing surgery under general anesthesia with laryngeal mask airway placement.\n\nExclusion Criteria:\n\n* Patients without the need for invasive airway management or undergoing surgery requiring orotracheal intubation.\n* Patients with known craniofacial malformations.\n* Patients undergoing neck surgery.","3 Months","17 Years",{"count":118,"type":21},340,"This study was designed to improve understanding of some respiratory reactions that can occur after surgery, such as difficulty breathing or persistent cough. These events, technically called PRAE (postoperative respiratory complications), are common reactions in children who have undergone surgery, and our aim is to find out if there are signs that can help us predict them, reducing their incidence in the future.\n\nDuring surgery, the child will receive general anesthesia, which will put him or her to sleep and not feel pain. In this context, a laryngeal mask airway (LMA) will be used to help the child breathe. The laryngeal mask airway is a soft device that is placed in the throat and allows the airway to be kept open, making breathing possible. This is a standard tool that will be used during surgery regardless of participation in the study.\n\nThe aim of this study is to better understand the relationship between the correct positioning of the laryngeal mask airway, measured by a specific ultrasound score, and the frequency of postoperative respiratory events in pediatric patients. As previously stated, these complications are common and well known in pediatric anesthesia practice, and the study aims to explore whether adequate ultrasound assessment can help predict and prevent them in the future. The study aims to observe the position of the laryngeal mask airway through a simple ultrasound and verify whether there is a relationship between the way the mask is positioned and the possibility of postoperative respiratory events. This type of ultrasound is non-invasive and does not add risk to the child.\n\nThis ultrasound check will take place without affecting the normal treatment of the patient and does not involve any additional risk or discomfort.\n\nThe study is purely observational: this means that we will collect information without modifying in any way the care already foreseen for the child.\n\nThe laryngeal mask airway and neck ultrasound are already part of standard medical practice, and the study does not present any additional risks. In this case, it is only a matter of reporting in all children who will participate in the study the \"results\" of ecological story of the neck (which we will process according to a score) and to evaluate whether there is a relationship between this score and the occurrence of respiratory adverse events upon awakening.\n\nThe overall duration of the study is 24 months. In total, we expect to include about 340 patients.",[121],"Paediatric Airway","2025-02-05",{"date":124,"type":39},"2025-02-10",{"date":126,"type":21},"2025-03",{"date":128,"type":21},"2027-03",{"name":45,"class":46},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":84,"phases":140,"briefSummary":141,"conditions":142,"keywords":149,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":72},"100557917","integration-of-remote-monitoring-in-the-management-of-chronic-immunosuppressive-therapy-100557917","NCT06544343","Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy","Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy in Patients With Rheumatologic Diseases: Comparison With Standard Management","TEMPLATE","Inclusion Criteria:\n\nAny patient with one of the following conditions\n\n* Rheumatoid Arthritis\n* Psoriatic Arthritis\n* Spondyloarthritis\n* Ankylosing Spondylitis\n* Systemic Sclerosis\n* Systemic Lupus Erythematosus\n* Sjogren's Disease who are prescribed a new immunosuppressive medication for the treatment of their disease among the following:\n* Methotrexate\n* Sulfasalazine\n* Leflunomide\n* Mycophenolate Mofetil\n* Azathioprine\n* Cyclosporine A\n* Tacrolimus\n* TNF inhibitors (etanercept, adalimumab, golimumab, certolizumab pegol)\n* IL6 inhibitors (tocilizumab)\n* IL-17 inhibitors (secukinumab, ixekizumab)\n* IL-23 inhibitors (ustekinumab, guselkumab, risankizumab)\n* JAK-inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib)\n* Belimumab\n* Anifrolumab\n\nExclusion Criteria:\n\n* Treatment with a medication not approved for the condition\n* Inability to use a device for remote call, not even with the help of a caregiver",{"count":139,"type":21},190,[86],"Systemic autoimmune and chronic inflammatory diseases are a group of chronic illnesses whose treatment is usually very prolonged, often lifelong, and is essential to keep the disease under control, thus reducing the risk of complications and allowing the best possible quality of life for patients.\n\nThe drugs used for treating these diseases are mostly immunosuppressants, which reduce the activity of the immune system, whose alteration is responsible for the disease. Although all available drugs are effective for treating these diseases, for reasons largely unknown, each drug is effective only in a percentage of patients. As a result, it is often necessary to try several different treatments before identifying an effective one for the individual patient.\n\nThe therapeutic effects are often slow, and it is therefore necessary to take a treatment for weeks or months before its effectiveness can be determined. The initial period is also when side effects most often appear. The aim of this study is to evaluate whether the addition of remote monitoring visits and other patient support services to traditional periodic medical visits in the first months after the introduction of a new treatment leads to an improvement in adherence, response, and quality of life for the patient.",[143,144,145,146,147,148],"Rheumatoid Arthritis","Psoriatic Arthritis","Systemic Lupus Erythematosus","Systemic Sclerosis","Spondyloarthritis, Axial","Ankylosing Spondylitis",[150,151],"Immunosuppression","Quality of Life","2024-08-06",{"date":154,"type":39},"2024-08-09",{"date":156,"type":39},"2024-07-01",{"date":158,"type":21},"2026-03-18",{"name":45,"class":46},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":4},"100509397","anatomical-variation-in-rouvires-sulcus-100509397","NCT05912894","Anatomical Variation in Rouvière's Sulcus","Anatomical Variation in Rouvière's Sulcus: a Cross-sectional Study","Inclusion Criteria:\n\n* Patients undergoing videolaparoscopic cholecystectomy\n\nExclusion Criteria:\n\n* If the lower face of the right hepatic lobe and the main elements of the biliary tract cannot be clearly analyzed patients will be excluded.",{"count":168,"type":21},1000,"Rouvière's sulcus is a 2-5 cm fissure lying on the lower face of the liver, between the right lobe and caudate process. Due to its extrabiliary location, Rouvière's Sulcus could be used as an anatomical landmark for safe laparoscopic cholecystectomy. In literature there's an high variability about Rouvière Sulcus prevalence and its anatomical variants.",[171],"Rouvière's Sulcus",[173,174],"Prevalence Rouvière's Sulcus","Anatomical variations Rouvière's Sulcus","2024-07-02",{"date":177,"type":39},"2024-07-05",{"date":179,"type":21},"2024-09-01",{"date":181,"type":21},"2026-08-31",{"name":45,"class":46},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":190,"minAge":18,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":72},"100484301","ultra-hypofractionated-radiotherapy-in-breast-cancer-patients-100484301","NCT05586256","Ultra-hypofractionated Radiotherapy in Breast Cancer Patients","Ultra-hypofractionated Adjuvant Radiotherapy After Breast Conserving Surgery in Breast Cancer Patients","Inclusion Criteria:\n\n* Female patients\n* Age ≥ 18 years.\n* Early stage breast cancer treated with breast conserving surgery\n* Whole breast irradiation without regional nodal irradiation\n* Infiltrating carcinomas\n* CDIS\n* Written informed consent\n\nExclusion Criteria:\n\n* Age\\\u003C18 years.\n* Regional nodal radiotherapy.\n* Distant metastases.\n* Previous history of malignancy except basaloid skin tumours and CIN. Previous history of breast cancer is not an exclusion criteria if treated with curative intent and if patient is disease free at least 5 years from diagnosis.\n* Presence of absolute radiotherapy contraindications (pregnancy, inability to maintain the correct treatment position) and relative radiotherapy contraindications (connective tissue diseases including rheumatoid arthritis, scleroderma, systemic lupus erythematosus, dermatomyositis and vasculitis, especially if the disease is in an active phase)\n* Patient's refusal to use data for research purposes.","FEMALE","99 Years",{"count":193,"type":21},300,"The present multicenter, retrospective and prospective observational study, aims to evaluate an ultra-hypofractionated whole breast irradiation schedule (WBI, 26 Gy in 5 fractions), in order to confirm literature data (FAST-F study) in the clinical practice.\n\nPatient population included women affected by early stage breast cancer (BC), both invasive and ductal carcinoma in situ, receiving ultra-hypofractionated WBI (with or without a tumor bed boost) after breast conserving surgery (BCS). Main exclusion criteria are mastectomy and regional nodal irradiation. Neoadjuvant and\u002For adjuvant systemic therapies are allowed. The primary otcome is acute and chronic toxicity evaluation. Secondary outcomes are: overall servival (OS), disease-free survival (DFS), rates of local and loco-regional recurrences, distant metastasis occurrence, cosmetic outcome and quality of life (QoL) assessment. Acute and late toxicities will be scored according to the Common Terminology Criteria for Adverse Events (CTCAE) scale version 5.0. Cosmetic assessment will be graded according to the Harvard scale. Frontal photographs of both breasts will be used to evaluate toxicity and cosmetic results. For QoL assessment the EORTC (European Organisation for Research and Treatment of Cancer), QLQ-C30 and EORTC-QLQ-BR23 questionnaires will be administered.",[196],"Female Breast Cancer",[198,199,200],"early stage breast cancer","breast conserving surgery","ultra-hypofractionated whole breast irradiation","2022-10-16",{"date":203,"type":39},"2022-10-19",{"date":205,"type":39},"2021-07-21",{"date":207,"type":21},"2026-07-21",{"name":45,"class":46},""]